Tehran University of Medical Sciences

Science Communicator Platform

Share By
Prognosis of Acute Myeloid Leukemia Based on Tp53 Mutation Among Adult Patients: A Systematic Review and Meta-Analysis Publisher



Ameli F ; Abdollahi A ; Valizadeh A ; Nozheh A
Authors

Source: Iranian Journal of Pathology Published:2026


Abstract

Background & Objective: Acute Myeloid Leukemia (AML) is a biologically diverse malignancy influenced by genetic abnormalities, with TP53 mutations playing a key role. Found in 5–10% of de novo AML and more common in therapy-related and secondary AML, TP53 mutations correlate with poor prognosis, chemoresistance, and reduced survival due to defective apoptosis and increased leukemic proliferation. These mutations often coexist with complex karyotypes and are more frequent in older patients, highlighting the need for improved prognostic tools and targeted therapies. This systematic review assessed the prognostic impact of TP53 mutations on overall survival (OS) and relapse-free survival (RFS) in adult AML. Methods: Following PRISMA guidelines, PubMed, Scopus, and Web of Science were searched through January 2025 for studies reporting OS and/or RFS by TP53 mutation status in adult AML. Data on study design, patient demographics, mutation frequency, and outcomes were extracted. Pooled hazard ratios (HRs) for OS and RFS were calculated using a random-effects model. Results: A total of 65 studies comprising over 6,000 adult AML patients were included in this systematic review and meta-analysis. The pooled HR for OS in TP53-mutated patients was 2.22 (95% CI: 2.08–2.37), indicating significantly worse survival than wild-type patients. For RFS, the pooled HR was 2.25 (95% CI: 1.98–2.56), reflecting a higher relapse risk. Heterogeneity was moderate for OS (I2=71%, p<0.01) and low for RFS (I2=0%, p=0.58). Conclusion: TP53 mutations strongly predict poorer overall and relapse-free survival in adult AML, supporting their integration into clinical risk models and emphasizing the need for novel therapeutic approaches in this high-risk subgroup. © 2026, Iranian Society of Pathology. All rights reserved.
Related Docs
View other Related Docs
1. Mutational Screening of Rtk-Braf Genes in De Novo Adult Acute Myeloid Leukemia, Gene Reports (2020)
2. Outcome of Acute Myeloid Leukemia Treatment and Isocitrate Dehydrogenase (Idh) Mutations: A Systematic Review and Meta-Analysis Study, International Journal of Hematology-Oncology and Stem Cell Research (2026)
3. Immunopathology and Immunotherapy of Myeloid Leukemia, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (4)
Shahrbano Rostami (2)
Other Related Docs
4. Toll-Like Receptor 4 Signaling Pathway Is Correlated With Pathophysiological Characteristics of Aml Patients and Its Inhibition Using Tak-242 Suppresses Aml Cell Proliferation, International Immunopharmacology (2021)
5. Inducing Apoptosis in Acute Myeloid Leukemia; Mechanisms and Limitations, Heliyon (2025)
6. Genetic Variants of Nucleotide Excision Repair Pathway and Outcomes of Induction Therapy in Acute Myeloid Leukemia, Personalized Medicine (2019)
7. Identification of Furo[2,3-D]Pyrimidin-4-Ylsulfanyl-1,3,4-Thiadiazole Derivatives As Novel Flt3-Itd Inhibitors, European Journal of Medicinal Chemistry (2024)
8. Studying the Potential of Upregulated Ptgs2 and Vegf-C Besides Hyper-Methylation of Ptgs2 Promoter As Biomarkers of Acute Myeloid Leukemia, Molecular Biology Reports (2022)
9. Investigation of Cebpa and Cebpa-As Genes Expression in Acute Myeloid Leukemia, Reports of Biochemistry and Molecular Biology (2019)
10. Ultrasensitive Quantitation of Flt3-Itd Mutation in Patients With Acute Myeloid Leukemia Using Ddpcr, Molecular Biology Reports (2023)
11. Natural Killer Cells and Acute Myeloid Leukemia: Promises and Challenges, Cancer Immunology# Immunotherapy (2022)
12. Reinforcing the Primary Immunotherapy Modulators Against Acute Leukemia; Monoclonal Antibodies in Aml, Immunotherapy (2019)
13. Rad51 and Rad50 Genetic Polymorphisms From Homologous Recombination Repair Pathway Are Associated With Disease Outcomes and Organ Toxicities in Aml, Blood Research (2024)
14. Transplantation, Clinical Immunology (2022)
15. Conditioning Intensity in Middle-Aged Patients With Aml in First Cr: No Advantage for Myeloablative Regimens Irrespective of the Risk Group-An Observational Analysis by the Acute Leukemia Working Party of the Ebmt, Bone Marrow Transplantation (2015)
16. Dendritic Cell Vaccination Strategy for the Treatment of Acute Myeloid Leukemia: A Systematic Review, Cytotherapy (2024)
17. Hotair Long Noncoding Rna Is Not a Biomarker for Acute Myeloid Leukemia (Aml) in Iranian Patients, Asian Pacific Journal of Cancer Prevention (2017)
18. High Expression of Long Noncoding Rna Norad Is Associated With Poor Clinical Outcomes in Non-M3 Acute Myeloid Leukemia Patients, Hematology/ Oncology and Stem Cell Therapy (2023)
19. Effects of Different Autophagy Inhibitors on Sensitizing Kg-1 and Hl-60 Leukemia Cells to Chemotherapy, IUBMB Life (2021)